Introduction
The lifetime risk for the development of colorectal cancer (CRC) in the general population is approximately 2%, and in Western countries it is 3-4% [1] . CRC accounts for 8% of all cancer deaths worldwide [1] . Numerous factors lead to an increased risk of CRC. Inheritable forms of CRC only account for 3-5% of all cases. If left untreated, the lifetime risk of developing CRC increases up to 80% for Lynch syndrome (formerly known as hereditary non-polyposis colorectal cancer or HNPCC) and up to 100% for familial adenomatous polyposis (FAP). Other risk factors include inflammatory bowel disease (IBD), with a 1.7-to 2.4-fold CRC risk increase compared with the general population [2, 3] , other polyposis syndromes (such as MUTYH-associated polyposis or juvenile polyposis syndromes) and unknown genetic mutations resulting in a familial aggregation of CRC cases (2-to 6-fold increase). Besides genetic alterations and chronic intestinal inflammation, Western lifestyle influences CRC developmenta high intake of alcohol and red meat, cigarette smoking, obesity and lack of regular physical activity are important and potentially avoidable risk factors.
Endoscopic surveillance, early detection and early surgery have become the main strategies to tackle this problem as late stages of CRC are difficult to treat, cost-intensive and lethal. As an adjunct to these measures, primary cancer prevention with pharmaceuticals, phytochemicals and/or dietary agents has become the standard of care in certain high-risk populations. This review will focus on primary chemoprevention in IBD, FAP and Lynch syndrome patients.
Inflammatory Bowel Disease
It is a well-known fact that patients with ulcerative colitis (UC) and colonic Crohn's disease (CD) have an increased risk for the development of CRC. The extent, severity, early onset and duration of the disease, as well as the coexistence of primary sclerosing cholangitis (PSC) and a family history of CRC, are well-established risk factors [4, 5] . A meta-analysis carried out in 2001, including 116 studies, estimated the prevalence of CRC in any UC patient to be 3.7% (95% CI 3.2-4.2), with cumulative probabilities of 2, 8 and 18% by 10, 20 and 30 years, respectively [6] . A meta-analysis of CD patients, including 6 publications, reported a comparable CRC risk with a standardized incidence ratio (SIR) of 1.9 (95% CI 1.4-2.5) [7] . Only Crohn's patients with colonic involvement had a 4.5-times greater CRC risk. Crohn's ileitis did not trigger colonic cancer risk (relative risk, RR, 1.1, 95% CI 0.8-1.5), again pointing to the fact that colonic inflammation itself is the main cause in such patients [8] . A recent meta-analysis of population-based cohort studies found a declining risk for CRC in IBD with a SIR of only 1.7 (95% CI 1.2-2.2) [2] . High-risk groups identified were, as also previously found, IBD diagnosis before the age of 30 with a SIR of 7.2 (95% CI 2.9-17.8) and extensive colitis with a SIR of 6.4 (95% CI 2.4-17.5). Another study published a year earlier showed similar results with respect to a decreasing CRC incidence, with a SIR of 2.4 (95% CI 2.1-2.7) for UC patients within 14 years of follow-up [3] . Another populationbased study from Denmark even found no increased CRC risk in IBD (RR 1.07, 95% CI 0.95-1.21) [9] , which is an extension to what was published earlier from the same cohort [10] . Only subgroups with an onset of UC in childhood or concomitant PSC remained at increased risk. The authors concluded that the decreased risk of CRC in IBD patients might be the result of improved therapies for IBD, including mesalazine (5-aminosalicylic acid, 5-ASA), thiopurines and TNF-α antagonists, and high colectomy rates.
Mesalazine 5-ASA, the first-line therapy for mild-to-moderate UC and for maintaining remission, is an anti-inflammatory agent with proposed chemopreventive properties. Despite the fact that the drug causes mucosal healing in the majority of patients, its chemopreventive effect is still under debate after decades of clinical use. Extensive research on the molecular actions of 5-ASA support both its anti-inflammatory and antineoplastic properties. 5-ASA is a potent scavenger for reactive oxygen species [11] , interferes with TNF-α/TGF-β/NF-κB pathways [12, 13] , and has antimicrobial activity [14] . Furthermore, 5-ASA induces apoptosis [15] , targets eukaryotic translation initiation factors [16] , induces S-phase arrest [17] , and improves replication fidelity [18, 19] , thereby reducing microsatellite instability, which has recently also been shown in an inflammation-independent model of CRC [20] . Other functions of 5-ASA include interference with the WNT/β-catenin and MAPK/ERK pathways and an increase in cell adhesion, with PAK1 as a common mediator, which is downstream of Rac1 [21, 22] . Several cohort and case-control studies investigating the chemopreventive properties of 5-ASA have been published, with controversial results. A meta-analysis, including 3 cohort and 6 case-control studies published between 1996 and 2004, showed a protective effect of 5-ASA for CRC, with an OR of 0.51 (95% CI 0.37-0.69) [23] . An epidemiological study based on the UK General Practice Research Database found a decreased risk of CRC for regular 5-ASA users compared with irregular users, with an OR of 0.6 (95% CI 0.22-0.96) [24] . A populationbased study carried out in Canada failed to show such a protective effect [25] . Another meta-analysis of non-referral populations also did not find a protective effect for CRC in IBD (adjusted OR 0.95, 95% CI 0.66-1.38) [26] . The same publication showed a protective effect for a meta-analysis of 9 clinic-based studies, with a pooled OR of 0.58 (95% CI 0.45-0.75). At this point, the chemopreventive effect of 5-ASA in UC is difficult to prove in a prospective placebo-controlled trial, as it is considered unethical to withhold such an active drug with an excellent safety profile from any UC patient.
Thiopurines
Azathioprine and its metabolites, 6-mercaptopurine and thioguanine, are used for the treatment of IBD, either alone or in combination with other drugs. The mechanism of azathioprine within the gut is attributed to its action on CD4+ T lymphocytes by inhibiting the small GTPase Rac1, thereby inducing apoptosis, which is mediated by the metabolite 6-thioguanine-triphosphate [27] . This is the same Rac1 which activates PAK1, a known target of 5-ASA (see above). A Dutch IBD cohort study compared thiopurine and 5-ASA users with nonusers for the development of advanced colorectal neoplasia, defined by high-grade dysplasia and CRC, resulting in a protective effect for both thiopurine and 5-ASA, with adjusted hazard ratios of 0.10 (95% CI 0.01-0.75) and 0.56 (95% CI 0.22-1.4), respectively [28] . A recent metaanalysis, including 9 case-control and 10 cohort studies, documented a decreased CRC incidence in patients treated with thiopurines, with an RR of 0.71 (95% CI 0.54-0.017) [29] . CESAME, a large French prospective IBD cohort, was initiated to monitor cancer risk in IBD patients. Among patients with long-standing extensive colitis, thiopurine intake was protective for colorectal high-grade dysplasia and CRC, with a hazard ratio of 0.28 (95% CI 0.1-0.9) compared with non-users [30] . Despite the anti-inflammatory and potential protective effect of azathioprine on CRC development, the risk for other cancers might be increased, particularly for nonmelanoma skin cancer (NMSC) and lymphoma. A publication based on the CESAME cohort reported an increased risk for NMSC for current and past thiopurine exposure, with hazard ratios of 5.9 (95% CI 2.1-16.4) and 3.9 (95% CI 1.3-12.1), respectively [31] . In a retrospective nested case-control study, Long et al. [32] showed that recent or persistent thiopurine use was associated with NMSC in CD patients, with ORs of 3.56 (95% CI 2.81-4.50) and 4.27 (95% CI 3.08-5.92), a correlation which was not seen in a Dutch patient cohort [33] . A UK population-based case-control study found an association of lymphoma development with azathioprine intake, with an OR of 3.22 (95% CI 1.01-10.18) [34] . Similarly, in a Danish IBD cohort study the rate ratio for overall cancer risk was 1.41 (95% CI 1.15-1.74), comparing non-users to azathioprine users, which was not found for patients who discontinued the use of azathioprine [35] . IBD patients treated with thiopurines, due to the potential increased risk of other cancers, should have lifelong dermatological and lymphoma screening and appropriate counselling and should avoid exposure to UV radiation. Nevertheless, thiopurines have a protective effect for the prevention of CRC, specifically in the setting of long-standing UC and Crohn's colitis.
TNF-α Antagonists
Antibodies against TNF-α such as infliximab, adalimumab and certolizumab, used alone or in combination with standard therapy, have been shown to reduce clinical symptoms and induce mucosal healing in patients with luminal or penetrating CD and in patients with moderate-to-severe UC who are refractory to other medications [36] . In a Danish population, the frequency of severe adverse reactions to infliximab was 3.3%, and the risk of cancer (especially lymphomas) was not increased; however, mortality was significantly higher than expected [37] . In contrast, in a nested case-control study, it has been shown that recent or persistent biological use among patients with CD was associated with NMSC (OR 2.07, 95% CI 1.28-3.33 and OR 2.18, 95% CI 1.07-4.46, respectively) [32] . A more recent meta-analysis compared the effect of adalimumab monotherapy with that of combination therapy (with thiopurine or methotrexate) in CD patients. The authors found an increasing risk for NMSC and other malignancies, with SIRs of 4.59 (95% CI 2.51-7.70) and 3.04 (95% CI 1.66-5.10), respectively [38] . In the context of chemoprevention, it is too early to judge biological agents in IBD as they have been implemented only 15 years ago. As persistent inflammation is considered the main driver for colitis-associated cancer, any drug that induces and maintains mucosal healing has the potential for reducing CRC risk.
Ursodeoxycholic Acid
PSC is strongly associated with IBD, as is the risk of developing colorectal neoplasia [39] . Ursodeoxycholic acid (UDCA), the first-line medication for the treatment of PSC, is considered chemopreventive for CRC.
A follow-up study investigating the long-term effect of UDCA in IBD patients with PSC found a protective effect on colorectal neoplasia development (RR 0.26, 95% CI 0.07-0.99) with a mean treatment time of 42 months at low dose (<15 mg/kg) [40] . A similar study reported a decreased prevalence of colonic neoplasia (OR 0.18, 95% CI 0.05-0.61) after 3.5-4.5 years with <10 mg/kg of UDCA [41] . In contrast, high-dose treatment with UDCA >15 mg/kg did not show a protective effect after 5 years [42] . In line with this, treatment with even higher doses (approx. 30 mg/kg UDCA) increased the risk of dysplasia or CRC (hazard ratio 4.44, 95% CI 1.3-20.1) [43] . Similarly, a retrospective analysis did not show a significant effect on dysplasia or CRC outcome after a mean intake of 3.4 years [44] . A meta-analysis from 7 publications revealed an overall non-significant risk reduction for patients treated with UDCA, especially at low and medium dosages [45] . In conclusion, current data suggest a trend for CRC risk reduction in PSC/IBD patients treated with UDCA <15 mg/kg, whereas higher doses seem to increase the risk. Of note, UDCA is not effective for polyp regression in FAP patients [46] .
Familial Adenomatous Polyposis
Germline mutations in the adenomatous polyposis coli gene are inherited in FAP. A second somatic mutation, which is commonly a missense mutation in the somatic mutation cluster region (codons 1,250-1,450), results in the appearance of hundreds and thousands of polyps, mainly found in the large bowel, ultimately progressing into CRC [47] . In addition, duodenal and small intestinal polyps are found in 90% of all FAP patients and with specific FAP mutations certain other extraintestinal tumours are also found (e.g. desmoid tumours, osteomas; fig. 1 ). Different variants of FAP exist, which are less common and more benign, such as attenuated FAP or MUTYH-associated polyposis. As the disease phenotype is clinically obvious, FAP is a great human model for studying chemoprevention in the colon.
Non-Steroidal Anti-Inflammatory Drugs
The main action of most non-steroidal anti-inflammatory drugs (NSAIDs) is attributed to the inhibition of cyclooxygenases (Cox). Cox-independent mechanisms involve NF-κB inactivation and β-catenin pathway inhibition [48] . Gastrointestinal side effects of NSAIDs are mostly associated with Cox-1 inhibition. Specific Cox-2 inhibitors such as celecoxib have fewer gastrointestinal side effects but more cardiovascular events, which led to the market withdrawal of rofecoxib in 2004 [49] . Similar cardiovascular toxicity has also been reported for NSAIDs (such as diclofenac), which can be considered as non-selective Cox inhibitors.
Sulindac
This non-selective Cox inhibitor, which is metabolized into its active compounds sulindac sulphide and sulphone, has been extensively studied in FAP with positive results. In 1991, the first randomized, placebo-controlled study demonstrated a protective effect of sulindac on rectal polyp formation. After 4 months of sulindac (300 mg/ day) a complete polyp regression was observed in 6/9 patients and none was observed in the placebo group [50] . or placebo for 9 months. The mean number of polyps and the mean diameter regressed to 44 and 35%, respectively; 3 months after sulindac treatment, some polyps rose again but remained fewer than at baseline [51] . Similarly, a trend towards reduced duodenal polyps was found in 24 colectomized FAP patients, and rectal polyps decreased [52] . Another study reported polyp regression after 60 days of 200 mg/day of sulindac [53] .
Local, low-dose rectal therapy in colectomized patients achieved complete polyp disappearance in 13 of 15 patients without relapse for over 2 years [54, 55] . Interestingly, in 41 FAP children before the primary polyp appearance, sulindac did not show a protective effect on the primary occurrence of adenomas [56] . Few data exist on the long-term effects of sulindac. A prospective study at moderate doses found a decrease in polyp numbers after 12 months as well as after a mean of 5 years, though rectal mucosal erosions were reported at the ileorectal anastomosis [57] . A retrospective study in patients with ileorectal anastomosis pointed out a non-significant effect after 4 years, although data at 6 months were significant [58] . Compliance is definitely an issue with long-term therapy. No association exists between the location of the adenomatous polyposis coli gene mutation and the response to sulindac [59, 60] . More distinct endoscopic approaches with chromoendoscopy revealed a decrease in polyp protrusions [60] . These morphological changes from protruding to flat lesions were also described by others [58, 61] . If undetected, such lesions might serve as precursors for CRC development. Long-term surveillance data for CRC development in FAP patients are missing. Sulindac is not available in many countries and thus its clinical use is limited.
Aspirin
Epidemiological data from large populations have pointed to the chemopreventive effects of aspirin [62] . The CAPP1 (Concerted Action Polyp Prevention 1), a randomized, placebo-controlled trial, investigated the effect of 600 mg of aspirin and/or 30 g of resistant starch for a minimum of 1 year in 200 FAP carriers. Aspirin, but not resistant starch, decreased the size of the largest polyp but not polyp numbers [63] . In a Japanese FAP cohort a similar effect on size reduction was observed with 100 mg for 6-10 months [64] .
Celecoxib
Compared with sulindac, aspirin or other NSAIDs, Cox-2 inhibitors have the advantage of reduced gastrointestinal side effects. In a randomized, double-blind, placebo-controlled trial the effect of adenoma regression upon treatment with 100 or 400 mg of celecoxib twice a day for 6 months was investigated in 77 adult FAP patients [65] . A dose-dependent effect of celecoxib on adenoma regression was found, whereas only the high-dose group showed a significant reduction in both the mean polyp number and polyp burden. A similar study assessing the effect on duodenal polyposis reported an effect at 400 mg twice daily [66] . In line with this, a dose escalation study in children found a dose-dependent decrease of polyps after 3 months at up to 16 mg/kg [67] . A clinical trial with 61 FAP patients treated with 150-200 mg of tiracoxib, another Cox-2 inhibitor, did not show any effect, which underlines the importance of appropriate dosing [68] . At this point celecoxib is the standard of care for patients before and after colectomy.
Lynch Syndrome
This hereditary CRC syndrome (formerly known as hereditary non-polyposis colorectal cancer or HNPCC), has an estimated incidence of 1-4% among all patients with CRC [69, 70] . It is caused by a germline mutation in one of four DNA mismatch repair genes (MSH2, MLH1, PMS2, or MSH6), leading to a hypermutable condition that fosters cancer development. One of the key features in Lynch syndrome tumours is microsatellite instability, which describes frameshift mutations in repetitive DNA sequences. Depending on the genetic defect, Lynch syndrome cancers may occur before the age of 50 (with mutations in MSH2 and MLH1) or even beyond 60-70 years of age (for MSH6 and PMS2 mutation carriers) [71] . Other typical features are synchronous and metachronous tumours, right colonic location, extracolonic cancer (e.g. endometrial, gastric, urogenital/bladder; fig. 2 ), and an autosomal dominant pattern of inheritance [72] . Despite this syndrome being far more common than FAP, mutation carriers are rarely identified as the disease phenotype is less obvious than in FAP.
The CAPP2 study was the first prospective, randomized, placebo-controlled, double-blind, multicentre, interventional trial to evaluate the effect of aspirin (600 mg) and/or resistant starch (30 pirin nor resistant starch (or a combination of both) had a preventive effect on intestinal neoplasia after a mean intake of 29 months [73] . A secondary analysis conducted 4 years after completion of the trial indicated a possible late effect of aspirin on cancer incidence [74] . A current goal is to replicate this post hoc analysis in a randomized, double-blind, non-inferiority, dose-finding study -CAPP3 [75] . Based on its chemopreventive effects in UC, its molecular improvement of replication fidelity and recent data in a mouse model of Lynch syndrome, another group of investigators just received funding from the European Union to evaluate mesalazine in Lynch syndrome carriers (MesaCAPP) [18, 20, 23, 76] .
Dietary Supplements and Phytochemicals
Reliable data on dietary supplementations or phytochemicals in patients at high risk for CRC are scarce. Fatty acids, calcium, folic acid, wheat fibre, vitamin C/E and curcumin/quercetin have been studied in FAP patients. Several studies are ongoing with regards to curcumin in FAP or IBD patients [77] .
ω-3 long-chain polyunsaturated fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid, are found at high concentrations in fish oil. An inverse relation exists between fish intake and CRC risk [78] and data on the anticarcinogenic effect of ω-3 polyunsaturated fatty acids accumulate [79] . A phase III randomized, double-blind, placebo-controlled trial in FAP patients with 2 g of eicosapentaenoic acid demonstrated both a reduction in polyp number and polyp burden [79] .
Small studies evaluating the effect of calcium or vitamin supplementation on FAP patients have been published decades ago with some promising effects. The treatment of 5 FAP patients with 3 g/day of ascorbic acid for 4-13 months led to a total and partial regression of rectal polyps in 2 patients each, whereas polyps increased in 1 patient [80] . A randomized placebo-controlled study in 36 FAP patients found a significant reduction in polyp area in patients receiving 3 g/day of ascorbic acid [81] . The intake of grain fibre, vitamin C and vitamin E for a period of 4 years was evaluated in another 58 FAP patients. A trend towards polyp reduction in the high-fibre group was found, but not for vitamin intake [82] . Also, calcium carbonate over 6 months in FAP patients had no significant effect on the reduction of polyp number or disease progression [83] . Supplementation with folic acid in UC patients reduced neoplasia development, with an RR reduction of 0.72 (95% CI 0.28-1.83), and was more effective at higher concentrations [84] . 
Combination Therapy
The combination of several single compounds should optimize the chemopreventive properties while reducing drug concentrations and adverse events. Both the CAPP1 and CAPP2 studies were actually designed to also test the potential combinatorial effects of aspirin and resistant starch [63, 73] . To date only a few other studies exist in FAP cohorts. A small series tested the combination of the nutritional supplements curcumin and quercetin for their efficacy in adenoma regression. Treatment lowered the number and size of polyps [85] . The combination of celecoxib (400 mg twice daily) and high-dose UDCA was used for duodenal polyp regression. Single celecoxib treatment decreased duodenal polyp density, while combination therapy even reversed such an effect [86] . In addition, UDCA per se had no effect on duodenal polyp regression in a separate study [46] . To date, the number of studies on combinatorial treatment is limited. In IBD, combination therapies such as mesalazine and thiopurines are widely used in medical practice without proper knowledge of such effects and potential drug interactions [5] .
Conclusions
Various drugs have been investigated for their chemopreventive capabilities in high-risk populations, some of them showing protective effects on long-term application ( fig. 3 ) . The incidence of colitis-associated CRC has diminished in the last decades. This decrease might be attributed to active drugs, probably mostly by decreasing inflammation and increasing mucosal healing. Although controversially discussed, treatment with 5-ASA or thiopurines as CRC chemopreventive drugs is advisable in patients with long-standing UC and Crohn's colitis, respectively. Such drug effects may even help reduce the necessity for annual surveillance colonoscopy as intervals could be stretched [90] . In FAP, celecoxib reduces polyp formation and subsequent CRC development, but still prophylactic surgery seems unavoidable. The effects of celecoxib are clinically more relevant in attenuated FAP when patients desire to keep their colons. The biggest medical need is in Lynch syndrome, when patients can choose between questionable effects of 600 mg of aspirin, which come with significant gastrointestinal adverse events, or a watch-and-wait strategy with annual colonoscopy. Mesalazine seems to be the proper candidate for these patients but, even more importantly, the unknown gene carriers need to be identified, at least for the sake of cancer-screening programs. A proper identification of unknown mutation carriers can only be achieved when index cases are tested for microsatellite instability and expression of mismatch repair proteins in the tumour samples. Such pathological tests are recommended for all CRC tumour samples from patients under 70 years [69] . This approach needs the collaboration of surgeons, gastroenterologists, pathologists and oncologists. It is time to implement such a strategy on a broader scale.
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